

an effective amount of hydroxylated atorvastatin metabolite; and
pharmaceutically acceptable carrier or diluent,
the effective amounts of amlodipine and hydroxylated atorvastatin metabolite
coordinated to substantially inhibit lipid peroxidation in human low density
lipoprotein or lipid membrane to achieve a therapeutic effect.

4. The pharmaceutical composition of claim 1 wherein said amounts of amlodipine
and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid
peroxidation to the extent necessary to achieve the therapeutic effect of reducing
the risk of arterial and related heart disease.

6. The pharmaceutical composition of claim 1 wherein said amounts of amlodipine
and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid
peroxidation to the extent necessary to achieve the therapeutic effect of lowering
blood pressure.

7. The pharmaceutical composition of claim 6 wherein the coordination is such
that said blood pressure is lowered to a level consistent with a reduced risk of
arterial and related heart disease.

8. The pharmaceutical composition of claim 6 wherein the coordination is such
that said blood pressure is lowered to a level statistically equivalent to normal.

9. The pharmaceutical composition of claim 1 wherein the amounts are
coordinated such that systemic lipid concentrations are lowered.

10. The pharmaceutical composition of claim 9 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of lowering systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

11. The pharmaceutical composition of claim 9 wherein said systemic lipid concentrations are lowered to a level statistically equivalent to normal.

12. The pharmaceutical composition of claim 1 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of lowering blood pressure and systemic lipid concentrations.

13. The pharmaceutical composition of claim 12 wherein said blood pressure and systemic lipid concentrations are lowered to a level consistent with a reduced risk of arterial and related heart disease.

14. The pharmaceutical composition of claim 12 wherein said blood pressure and systemic lipid concentrations are lowered to a level statistically equivalent to normal.

22. A pharmaceutical composition comprising:

a therapeutically effective amount of a combination of amlodipine and - hydroxylated atorvastatin metabolite; and

pharmaceutically acceptable carriers or diluents wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations at least partially as a result of reduced lipid oxidation.

25. The pharmaceutical composition of claim 22 wherein said therapeutically effective amount is selected such that the risk of arterial and related heart disease is reduced.

27. The pharmaceutical composition of claim 22 wherein said therapeutically effective amount is selected such that blood pressure and systemic lipid concentrations are lowered to a level consistent with a reduced risk of arterial and related heart disease.

28. The pharmaceutical composition of claim 22 wherein said therapeutically effective amount is selected such that blood pressure and systemic lipid concentrations are lowered to a level statistically equivalent to normal.

57. A pharmaceutical composition comprising:

an amount of amlodipine;

an amount of hydroxylated atorvastatin metabolite; and

pharmaceutically effective carriers or diluents.

Please add the following claims:

63. A pharmaceutical composition comprising:

an amount of amlodipine;
an amount of hydroxylated atorvastatin metabolite; and
a pharmaceutically acceptable carrier or diluent;
wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that an antioxidant effect is achieved by the combined amounts which is greater than the antioxidant effect of either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.

64. A pharmaceutical composition comprising:

an amount of amlodipine;
an amount of hydroxylated atorvastatin metabolite; and
a pharmaceutically acceptable carrier or diluent;
wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that the inhibition of lipid peroxidation achieved by the combined amounts is greater than the inhibition of lipid peroxidation achieved by either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.

65. The pharmaceutical composition of claim 64 wherein said selection is further coordinated for achieving an antioxidant effect, which effect is greater than the antioxidant effect achieved by said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite independently.

Please cancel claims 15-21.

REMARKS

The Office Action of March 20, 2002 has been carefully reviewed and this response addresses the Examiner's concerns. Claims 1-62 were pending in the application. Claims 1-28 and 57-59 stand rejected. Claims 1, 4, 6-14, 22, 23, 27, 28, and 57 are herein amended, and such claims effectively change dependent claims 2, 3, 5, 24-